Цель. Изучить субъективное мнение пациентов и врачей об их индивидуальном опыте приверженности лечению хронических заболеваний сердечно-сосудистой системы с помощью проведения группового фокусированного интервью пациентов и их лечащих врачей. На основании полученных данных сформулировать гипотезы о возможных взаимосвязях в модели отношений врач-пациент. Материал и методы. Проанализировано 3 группы пациентов клинических исследований, соблюдающих рекомендации врача (фокус-группа №1) и 3 группы пациентов, госпитализированных по поводу сердечно-сосудистого события, не соблюдающих рекомендации после выписки (фокус-группа №2), и одна фокус-группа врачей. Проводилась групповая беседа под руководством модератора (опытного социолога, без медицинского образования, не знакомого с пациентами и врачами). Результаты. Участвовало 47 пациентов: 25 (53,2%) мужчин и 22 (46,8%) женщины, и 6 врачей. В сознании всех пациентов присутствует патерналистская модель общения с врачами, но пациентов первой группы это приводит к полному доверию к врачу и соблюдению всех рекомендаций, а для пациентов второй группы недостаток помощи в поликлинике проявляется в «обиде» на недооценку их доверия и приводит к отказу от лечения. Врачи интуитивно делят пациентов на менее и более им «симпатичных», и это деление, с одной стороны, может иметь некоторую предсказательную ценность в отношении приверженности пациентов дальнейшему лечению, а с другой-предубеждение врача в отношении пациента может влиять на негативное поведение пациентов и невыполнение ими рекомендаций в дальнейшем. Заключение. Выраженный патернализм со стороны пациента, с одной стороны, повышает ответственность врача за своего больного, а с другой-расширяет возможности для его влияния на поведение пациентов. Ключевые слова: приверженность, комплаенс, невыполнение врачебных рекомендаций, сердечно-сосудистые заболевания, фокусированное интервью, фокус-группы, взаимоотношения врача и пациента. Рациональная фармакотерапия в кардиологии 2014;10(1):55-61 Adherence to long-term treatment of cardiovascular disease and non-compliance with medical recommendations: the opinion of patients and physicians by the results of focused interview

Use of high-flow nasal cannula (HFNC) for bronchiolitis has increased, but data describing the current use and impact of this therapy are limited. Our objective with this study was to describe the use of HFNC for bronchiolitis in a pediatric emergency department (ED) from 2013 to 2019 and to explore associations with clinical outcomes. METHODS:This was a retrospective cohort study of children aged 2 to 24 months with the diagnosis of bronchiolitis. The primary outcome was HFNC initiation in the ED. Secondary outcomes included admission rate, ICU (PICU) admission, transfer to PICU from floor, and endotracheal intubation. An adjusted interrupted times series analysis was performed to analyze changes in rates of primary and secondary outcomes over time. RESULTS:In total 11 149 children met inclusion criteria; 902 (8.1%) were initiated on HFNC. The rate of HFNC initiation increased from 1.3% in 2012-2013 to 17.0% in 2018-2019 (P trend # .001). Less than 30% of children initiated on HFNC were hypoxic. There were no significant changes over time in rates of hospital admission, PICU admission, or PICU transfer, adjusting for clinical severity, seasonality, and provider variation. Intubation rate increased over the study period. CONCLUSIONS:We found a 13-fold increase in HFNC use over a 6-year period with no evidence of improvement in clinically meaningful outcomes. Clinical benefit should be clearly defined before further expansion of the use of HFNC for bronchiolitis in the ED.

Documentation of children's tobacco smoke exposure (TSE) in the electronic health record (EHR) can have important implications for clinical care. However, it may not be accurate if it is not based on biochemical assessment, the most reliable method of verifying TSE. Our objectives were to compare the accuracy of EHR classification of TSE with cotinine verification and to explore parent and child variables associated with biochemically verified TSE. METHODS:Participants were 171 hospitalized pediatric patients (ages 0-17 years; mean age 5.1 [SD 3.7] years) who had EHR documentation of TSE and measured salivary cotinine. Children with cotinine levels .1 ng/mL were classified as having biochemical verification of TSE. Parents reported sociodemographic characteristics, and children's EHRs were abstracted for TSE status, past medical history, and diagnoses. We conducted x 2 tests to assess the agreement between EHR classification of TSE status and cotinine levels. Then, we assessed the relationship between sociodemographic and clinical variables and cotinine using crude and adjusted logistic regression models.RESULTS: Overall, 71% (121 of 171) of EHR classifications were correct on the basis of cotinine levels. Specificity analyses showed that 77% (53 of 69) were correctly identified as exposed to tobacco smoke. Sensitivity analyses showed that 67% (68 of 102) were correctly identified as unexposed. The negative predictive value was 0.61 (53 of 87); 39% (34 of 87) were misclassified as unexposed. The positive predictive value was 0.81 (68 of 84); 19% (16 of 84) were misclassified as exposed.CONCLUSIONS: Almost 40% of children were misclassified in the EHR as unexposed to tobacco smoke. Biochemical verification should be used as part of universal TSE screening during pediatric hospitalizations.

OBJECTIVE Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment influenced outcomes. RESEARCH DESIGN AND METHODS Patients with T2D, urine albumin-to-creatinine ratio (UACR) of 30–5,000 mg/g, estimated glomerular filtration rate (eGFR) of 25 to <75 mL/min/1.73 m2, and treated with optimized renin–angiotensin system blockade were randomly assigned to receive finerenone or placebo. Efficacy outcomes included kidney (kidney failure, sustained decrease ≥40% in eGFR from baseline, or renal death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) composite endpoints. Patients were analyzed by baseline insulin use and by baseline HbA1c <7.5% (58 mmol/mol) or ≥7.5%. RESULTS Of 5,674 patients, 3,637 (64.1%) received insulin at baseline. Overall, 5,663 patients were included in the analysis for HbA1c; 2,794 (49.3%) had baseline HbA1c <7.5% (58 mmol/mol). Finerenone significantly reduced risk of the kidney composite outcome independent of baseline HbA1c level and insulin use (Pinteraction = 0.41 and 0.56, respectively). Cardiovascular composite outcome incidence was reduced with finerenone irrespective of baseline HbA1c level and insulin use (Pinteraction = 0.70 and 0.33, respectively). Although baseline HbA1c level did not affect kidney event risk, cardiovascular risk increased with higher HbA1c level. UACR reduction was consistent across subgroups. Adverse events were similar between groups regardless of baseline HbA1c level and insulin use; few finerenone-treated patients discontinued treatment because of hyperkalemia. CONCLUSIONS Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.

No abstract

No abstract

The aim of our study is researching influence of vitamin D and osteocalcin polymorphic gene markers in people, who lived in Blockaded Leningrad in 1941-1944 and detecting “critical age” of peak bone mass formation in these people. We included in our study 48 peoples, 13 males and 35 females. Osteodensitometry of lumbar spine (L1-L4) and proximal hip was used by dualenergy X-ray absorptiometer GE Lunar Prodigy Vision 6. Molecular diagnostic researching are: detecting ApaI, TagI vitamin D receptor (VDR) and HindIII osteocalcin gene polymorphism by polymerase chain reaction with restriction assay. Women with osteopenia of hip neck had significantly higher age in the onset of Blockade, than women without osteopenia. Genotype ТТ and allele Т of TagI, aa genotype of ApaI VDR, genotype hh and allele h of HindIII osteocalcin gene polymorphism will be able as markers of genetic predisposing to osteoporosis in people, who lived in Blockaded Leningrad.

Aim. To study clinical, laboratory and psychological aspects of moderate coronavirus disease 2019 (COVID-19) in cardiovascular patients one month after discharge from the hospital.Material and methods. The study included 88 patients with cardiovascular diseases hospitalized for COVID-19. After 1 month, 72 respondents continued the participation in the study. Medical history collection, physical examination, and diagnostic investigations were performed. We used the Hospital Anxiety and Depression Scale (HADS) by Zigmond A. S., Snaith R. P., Beck Anxiety Inventory scale, Mini-mental State Examination (MMSE) scale for assessing mental status.Results. One month after discharge, there was a decrease in the number of patients with signs of impaired respiratory system, such as cough, shortness of breath, chest congestion, while a decrease in exercise tolerance persists was revealed in 80,5% (out of 95,5% during hospiatalization), generalized weakness and increased sweating — in 69,5%. In addition, 38,9% of patients noted a noticeable, newly reported, hair loss. Attention is drawn to the high prevalence of neurological symptoms during hospiatalization, including dizziness, severe headaches not relieved by analgesics and non-steroidal anti-inflammatory drugs, lethargy, disorientation of place and time, and in some cases even hallucinations. Some of the symptoms persist after 1 month: 55,5% note a decrease in memory, 36% — feelings of fear and anxiety, 63,9% — sleep disorders in the form of frequent nocturnal awakenings (19,4%), insomnia (16,6%), long falling asleep (11,1%). Some of the respondents revealed unfavorable events over the past month as follows: blood pressure (BP) destabilization in the form of episodes of BP increase and decrease during the day — 36,0%, hypertensive crisis — 14,0%. There was an increase in the number of patients with subclinical and clinical depression (p<0,05). There was also an increase in the number of patients with hypercholesterolemia compared with inhospital data by 15,5%.Conclusion. One month after discharge, the respiratory symptoms naturally decrease, but new symptoms appear, such as shortness of breath during exercise, fatigue, unsteady gait, hair loss, and increased sweating. There was an increase in the number of patients with subclinical and clinical depression on the HADS scale. Among laboratory parameters, an increase in the number of patients with increased level of total cholesterol and low-density lipoproteins was revealed.